Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 18.104.22.168) - Pipeline Review, H1 2018
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 22.214.171.124) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 126.96.36.199) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 2, 7 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Dermatology, Hematological Disorders, Cardiovascular, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Myelofibrosis, Atopic Dermatitis, Leukemias, Myeloproliferative Disorders, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alopecia, Glioblastoma Multiforme (GBM), Hematological Tumor, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Asthma, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Leukemia, Bleeding And Clotting Disorders, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Eczema, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Essential Thrombocythemia, Giant Cell Arteritis, Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Failure, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Thalassemia, Ulcerative Colitis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration.
The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 188.8.131.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 184.108.40.206) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook